


1

Bladder Cancer *Chemotherapy* + *Immunotherapy*

JAVELIN 100 Study

- 4 to 6 cycles of first-line platinum chemotherapy (gemcitabine + cisplatin or carboplatin) followed by avelumab vs BSC
- · Median overall survival
 - Avelumab: 21.4 months
 - BSC: 14.3 months
- Avelumab maintenance following platinumbased chemotherapy became standard treatment


BSC, best supportive care Powles T et al. N Engl J Med. 2020;383:1218




3


Immune Checkpoint Inhibitors


- ICIs stimulate T-cell– mediated killing of tumor cells by blocking recognition of tumor cells as "self"
- Targets include
 - Cytotoxic T lymphocyte– associated antigen 4 (CTLA4)
 - Programmed cell death 1 (PD-1)
 - Programmed cell death ligand 1 (PD-L1)




Centanni M et al. Clin Pharmacokinet. 2019;58:835

















Current MIBC Perioperative Trials Similar therapy continues as adjuvant (regardless of path stage) MIBC R 1:1 GC alone or no NAC Placebo or no adjuvant **KEYNOTE-905/EV-303 KEYNOTE-866** EV + pembrolizumab ×3 Cystectomy Pembrolizumab Cystectomy Pembrolizumab ×14 Placebo + GC ×4 Placebo No neoadjuvant therapy KEYNOTE-B15/EV-304 NIAGARA EV + pembrolizumab ×4 Durvalumab ×8 Cystectomy Cystectomy GC ×4 GC ×4 ve bladder cancer; EV, enfortumab vedotin; GC, gemcitabine + cisplatin; NAC, neoadjuvant cl Necchi A et al. J Clin Oncol. 2023;41. Abstract TPS585; Galsky MD et al. Future Oncol. 2021;17:3137; Powles TB et al. Annals Oncol. 2024;35. Abstract S1271; Holmes CJ et al. J Clin Oncol. 2021;39. Abstract TPS4587







Current MIBC Perioperative Trials





5





7

Putting NIAGARA in Context

Study	Treatment arm	pT0	1-year MFS	2 year MFS	2-year OS %
VESPER ^{1,2}	ddMVAC	42%	82%	73%	83%
	GC	36%	76%	61%	78%
NIAGARA ³	GC + durvalumab (pre/post)	37%	82%*	74%*	82%
	GC	28%	79%	68%	75%

*Patients who did not undergo radical cystectomy were censored.

ddMVAC, dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin; GC, gemcitabine and cisplatin 1. Pfister C et al. Annals Oncol. 2021;32:Abstract 6520. 2. Pfister C et al. Lancet. 2024;25:255. 3. Powles TB et al. Annals Oncol. 2024;35. Abstract S1271 Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer Episode 3: Patient Perspectives on Bladder Cancer



Skin reactions

- Seen with both EV and pembrolizumab but more frequently with combination (EVP)
- 70% of patients treated with EVP
- Management ranges from monitoring and emollients or topical steroids to holding or discontinuing both agents. depending on severity

Brower B et al. Front Oncol. 2024;14:1326715

Hyperglycemia/ diabetes mellitus


- Seen with both EV and pembrolizumab but more commonly with EV
- · 13% of patients treated with EVP
- Management includes treating with insulin and holding EV and/or pembrolizumab

Peripheral neuropathy

- Anticipated AE with ADCs, rarely with pembrolizumab
- Second most common AE: 67% of patients treated with EVP
- Management ranges from dose reduction and treatment for nerve pain to discontinuing both agents, depending on severity

1





Time to First Onset of Toxicities Enfortumab Vedotin vs Chemotherapy

		Median time to onset, months (range)			
Adverse	event	EV	Chemotherapy		
Skin read	tions	0.43 (0.03–12.68)	0.66 (0.07–9.56)		
Periphera	al neuropathy	2.81 (0.03–13.04)	0.85 (0.03–9.07)		
Hypergly	cemia	0.62 (0.26–13.37)	1.41 (1.41–1.41)		

EV, enfortumab vedotin Rosenberg J et al. Ann Oncol. 2023;11:1047.

Durable Responses Maintained With EV Despite Dose Modifications (EV-301)

			ADC C _{avg} Q1 ^a (n=74)	ADC C _{avg} Q2 ^b (n=74)	ADC C _{avg} Q3 ^c (n=74)	ADC C _{avg} Q4 ^d (n=74)	
	Median EV ADI (mg/kg/4 wee	k) ^e (range)	2.37 (1.15, 3.77)	2.96 (1.57, 3.82)	3.26 (2.36, 3.86)	3.59 (2.50, 3.93)	
	Any EV dose delay (%)		59.5	58.1	44.6	26.4	
Any EV dose reduction (%)		54.1	39.2	28.4	20.3		
	To 1.0 mg/kg		52.7	39.2	28.4	20.3	
	To 0.75 mg/kg		21.6	14.9	6.8	1.4	
	Median time to EV dose redu	ction (range), mo	2.02 (0.79, 9.27)	2.96 (0.95, 12)	3.06 (0.72, 6.64)	2.79 (0.89, 9.04)	
EV/	204.			Median DOR for responders by exposure quartile			
			ADC $C_{avg} Q1^a (n=27)$ ADC $C_{avg} Q2^b (n=33)$ ADC $C_{avg} Q3^c (n=26)$			7.39 (5.45, NE	E)
Median time to response: Median DO					6.44 (5.68, NE) (5.55, 4.86)		
1.9 months (range: 1.1–5.7)		ADC $C_{avg} Q3^{d} (n=20)$ ADC $C_{avg} Q4^{d} (n=31)$	7.62 (4.14, NE)				
All dat	a presented are from the post hoc, ex	ploratory analysis.	0	2	4 6 Months	8	
rage ADC	ly-drug conjugate; ADI, absolute dose intensi c exposures were divided into 4 quartiles: *Q1					ure quartile);	

Petrolek DD et el. / C/a Open/2024, 42: A betreet